Ibio, Inc. · NASDAQ:IBIO
Ibio — IPO Roadshow (October 2019)
24 slides from Ibio's IPO roadshow presentation, Oct 11, 2019
Slide 1: Enabling Next-Gen Biologics with the FastPharming System
Enabling Next - Gen Biologics with the FastPharming System TM • CDMO : Rapid delivery of eco - friendly, high - quality biologics for biotech, biopharm , academic and government clients • Therapeutics/Vaccines : Proprietary product development using FastPharming Technologies
Slide 2: Free Writing Prospectus Disclosure
Enabling Next - Gen Biologics • Issuer Free Writing Prospectus Issued Pursuant to SEC Rule 433 • This issuer free writing prospectus amends and replaces the free writing prospectus filed by iBio , Inc . (the “Company”) with the Securities and Exchange Commission on September 17 , 2019 and is being f
Slide 3: Forward-Looking Statements
Enabling Next - Gen Biologics Forward - Looking Statements 3 STATEMENTS INCLUDED IN THIS PRESENTATION RELATED TO IBIO, INC . MAY CONSTITUTE FORWARD - LOOKING STATEMENTS WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 . SUCH STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAI
Slide 4: Offering Summary
Enabling Next - Gen Biologics Offering Summary 4 Issuer iBio, Inc. Exchange / Ticker NYSE American: IBIO Offering Size Up to $10M (100% Secondary) Over Allotment 15% (100% Secondary) Offering Details Common Stock, Preferred Stock and Warrants Use of Proceeds We intend to use the net proceeds from th
Slide 5: Management Team
Enabling Next - Gen Biologics Robert B. Kay, CEO and Executive Chairman ▪ Accomplished business strategist, senior manager with M&A, JV, international licensing expertise ▪ JD from New York University (NYU); BA from Cornell University Thomas F. Isett, Strategic Advisor ▪ Business leadership for biop
Slide 6: New Management Actions: FQ4'19 – FQ1'20 Highlights
Enabling Next - Gen Biologics ▪ Refreshed strategy ▪ Enhanced brand & commercial capabilities ▪ New website & CRM ▪ Tradeshow and symposia plan ▪ Began hiring commercial team members ▪ Installed S&OP process to drive teamwork and financial rigor ▪ Re - evaluating proprietary product opportunities ▪
Slide 7: New Thrusts to Drive Shareholder Value
Enabling Next - Gen Biologics Core : Differentiate FastPharming System and gain share in $6B biologics CDMO market Adjacency : Enter high - growth 3D Bioprinting materials segment using FastPharming’s strengths Factory Solutions : Adding cannabis to existing tobacco “design & build” turn - key facil
Slide 8: Biological Medicines: Outsourcing Landscape
Enabling Next - Gen Biologics Discovery Validation Preclin Dev PD Phase I / II Phase III Regulatory Review Phase IV Biological Medicines: Outsourcing Landscape 13% 67% 12% 8% Preclinical Clinical Central Lab Others 36% 23% 32% 9% Consulting Auditing Regulatory Training/Ed ATIC Biologics CDMO Service
Slide 9: Redefined, Differentiated Core Biologics CDMO Service Offering
Enabling Next - Gen Biologics Redefined, Differentiated “Core” Biologics CDMO Service Offering 9 Process Development BioAnalytical Development Glycan Engineering cGMP Manufacturing Aseptic Fill - Finish Regulatory Consulting Factory Solutions NEW NEW NEW
Slide 10: Fill and Finish Services and FastPharming Biologics Mfg Services
Enabling Next - Gen Biologics Fill and Finish Services ▪ New F/F offering launched June 2019 ▪ First (gene therapy) client won mid - June ▪ Favorable market conditions (supply constraints) ▪ Line extension for 5mL fills planned for Q3’FY20 ▪ iBio revenue capacity >$10M with line extension iBio: diff
Slide 11: Meanwhile, iBio remains well-positioned
Enabling Next - Gen Biologics Meanwhile, iBio remains well - positioned… 11 0.0 100.0 200.0 300.0 400.0 500.0 2007 2009 2011 2013 2015 2017 2019 2021 2023 2025 Biologic Revenues ($B) Monoclonal Antibodies Recombinant Proteins Bioengineered Vaccines Viral Vaccines Cell Therapies 3D Bioprinting Stem c
Slide 12: iBio's FastPharming System uses Plants as Bioreactors
Enabling Next - Gen Biologics ▪ Faster: Saves months in initial setup vs. mammalian systems ▪ Better: x No expensive, labor intensive cell line development x Avoids scale up challenges – just plant more plants x More glycosylation controls to help increase potency x Lower upfront facility expense v.
Slide 13: "Pharming" going mainstream
Enabling Next - Gen Biologics “Pharming” going mainstream 13 “Compared with proteins derived from mammalian cells, proteins from genetically engineered plants are easy to scale up and synthesize with other proteins, and they remain stable at room temperature for longer periods” WSJ July 19, 2019 “…t
Slide 14: Supporting 3D-Bioprinting of Organs with the FastPharming System
Enabling Next - Gen Biologics 0 20000 40000 60000 80000 100000 120000 140000 160000 180000 Supporting 3D - Bioprinting of Organs with the FastPharming System 14 ▪ iBio’s production of biologics in plants is uniquely suited for the manufacture of advanced bioinks for 3D Bioprinting o Safer: Mammalian
Slide 15: Enabling Global Adoption of FastPharming with Turn-Key Factory Solutions
Enabling Next - Gen Biologics ▪ Opportunities in global, turn - key bioprocess facilities market ($2B) ▪ Facility design & build for clients using iBio’s FastPharming System: “In country, for country” ▪ Factory Solutions for plant - based bioprocessing without proprietary FastPharming technologies ▪
Slide 16: Investing in Asset Development for Anti-Fibrotic Therapies
Enabling Next - Gen Biologics Investing in Asset Development for Anti - Fibrotic Therapies 16 iBio Innovative Solution E4 Peptide ▪ E4 derived from endostatin ▪ Strong pre - clinical data v. standard of care ▪ Optimally produced in FastPharming System ▪ Intrinsic properties enable a product that cou
Slide 17: Breakthrough Anti-Fibrotic Therapies
Enabling Next - Gen Biologics Breakthrough Anti - Fibrotic Therapies Company Established 2008 - NYSE American Locations New York, NY (HQ) | Bryan, TX (Labs/Mfg) Tech Description E4 anti - fibrotic peptide [CFB - 03] & FastPharming TM System for biologics manufacturing Science E4 Peptide: Collagen XV
Slide 18: Dynamic, Continuing Invention with Appropriate Global Protection
Enabling Next - Gen Biologics U.S. Patents 22% International Patents 45% International Patent Applications 28% U.S. Patent Applications 5% ▪ 80+ issued patents in various countries (26 U.S.) ▪ 39+ active patent applications (6 U.S.) ▪ More applications progressing to filing ▪ Inventions address tech
Slide 19: iBio v. Fraunhofer
Enabling Next - Gen Biologics ▪ Memorandum opinion in Delaware Court of Chancery (2016) and other developments favor iBio ▪ Depositions expected to finish by October 2019; trial currently scheduled for May 4 - 15, 2020 ▪ Litigation costs and expenses related to current counsel fully funded through a
Slide 20: Value Proposition
Enabling Next - Gen Biologics ▪ Process Development ▪ cGMP Manufacturing ▪ Fill / Finish ▪ Bioanalytics ▪ Quality & Regulatory ▪ Factory Solutions Value Proposition 20 ▪ Speeds time - to - market vs. traditional approaches ▪ Powerful glycan engineering tools can increase potency, quality of clients’
Slide 21: Investment Summary
Enabling Next - Gen Biologics ▪ Differentiating offering in core biologics CDMO market to achieve valuations comparable to competitors ▪ Adding new services for Fill/Finish & 3D Bioprinting materials to create significant growth potential ▪ Enhancing Factory Solutions “design - and - build” services
Slide 22: Cap Table
Enabling Next - Gen Biologics Cap Table Type Issued Outstanding * Common Equivalent ** Full Conversion Common Stock 24,152,455 24,152,455 24,152,455 24,152,455 Series A Convertible Preferred Stock 6,300 387 430,000 24,582,455 Series B Convertible Preferred Stock 5,785 5,785 6,427,771 31,010,226 CMO
Slide 23: Contact
Contact 23 Company: iBio , Inc. Tom Isett: 443 - 955 - 4262 | tisett@ibioinc.com Jim Mullaney: 212 - 399 - 4294 | jmullaney@ibioinc.com Bank: AGP Chris Pravecek: 312 - 392 - 4257 | cp@allianceg.com
Slide 24: Enabling Next-Gen Biologics with the FastPharming System
Enabling Next - Gen Biologics with the FastPharming System TM • CDMO : Rapid delivery of eco - friendly, high - quality biologics for biotech, biopharm , academic and government clients • Therapeutics : Proprietary product development using FastPharming Tech for anti - fibrotic compounds and vaccine